Vas Narasimhan (Photographer: Simon Dawson/Bloomberg via Getty Images)
June 30, 2022 02:17 PM EDTUpdated 02:35 PM
FDA+

No­var­tis buys Mallinck­rodt's FDA vouch­er for $100M but re­mains mum on where to use its 7th PRV

Zachary Brennan

Senior Editor

No­var­tis on Thurs­day con­firmed to End­points News that it pur­chased a pri­or­i­ty re­view vouch­er from bank­rupt phar­ma com­pa­ny Mallinck­rodt, but the Swiss-Amer­i­can multi­na­tion­al com­pa­ny de­clined …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times